Share

In the past few years we have witnessed a significant rise in the use of biopharmaceutical and large molecule therapeutics. One of the results of this has been to make peptides and proteins popular drug discovery targets for the pharmaceutical and biotechnology industries. As such, peptide synthesis companies are playing an increasingly important role within the pharmaceutical industry as a whole.

Protein and peptide drugs, particularly antibodies, have high specificities and potencies with low toxicity incidences, which makes them attractive therapeutics for various therapy areas.

Industry leading peptide synthesis companies and protein manufacturing solutions

Our team at Pharmaceutical Technology has researched and listed some of the leading peptide synthesis companies and protein manufacturing solutions.

Of the companies we have included, most offer a wide range of important services and products.

These include custom peptide synthesis, peptide libraries and reagents, protected amino acids, unnatural amino acids and derivatives, active pharmaceutical ingredients (APIs) production, and good manufacturing practice (GMP) manufacturing.

Our well researched and professionally written download document contains a wide range of important industry insights.

This content will be of particular interest and value to pharmaceutical executives, research scientists, associates, chemists, business development managers, and other individuals involved in protein and peptide synthesis and manufacturing operations within the pharmaceutical industry.

Related Buyer’s Guides which cover an extensive range of pharmaceutical equipment manufacturers, solutions providers and technology, can also be found here.

Important and innovative protein synthesis and manufacturing techniques

Biotech drug manufacturing is a complex and time-consuming process. rDNA and hybridoma cell technologies allow for mass production of protein-based drugs, making the processes more cost-effective.

Despite this, the contamination removal processes for protein biological synthesis make it a more complicated and costly process than peptide synthesis.

In hybridoma cell technology, the fusion of certain white blood cells with hybridomas allows them to be replicated infinitely to produce monoclonal antibody protein-based therapies for the treatment of cancer and other diseases.

In rDNA technology, genes that encode for the required protein are transferred from one cell or organism to another, enabling bulk production of protein-based drugs.

Custom protein synthesis enables fast expression and purification of any protein as required. Pharmaceutical companies providing custom protein production services also offer bulk production of proteins for industrial projects.

Peptide manufacturing

Peptides are manufactured by solid-phase synthesis, solution-phase synthesis, and a combination of both. Solid-phase synthesis is a relatively simple technique that allows rapid production and easy upscaling.

Solution-phase peptide synthesis is more suitable for shorter peptide chains, while solid-phase synthesis is better-suited to longer and more complex amino acid sequences.

Peptides are used to design new enzymes, drugs and vaccines. Improvements in their production methods have made peptide synthesis more feasible for general research purposes.

FAQs

What are protein and peptide synthesis services in pharmaceutical development?

Protein and peptide synthesis involves the creation of complex molecules, such as therapeutic proteins and peptides, used in drug development.

These services include custom synthesis, large-scale production, and purification processes. Proteins are typically manufactured using recombinant DNA technologies, while peptides are synthesized through solid or solution-phase methods.

These molecules are essential for treatments in areas like oncology, immunology, and infectious diseases.

How do custom protein and peptide synthesis services benefit drug development?

Custom synthesis services allow pharmaceutical companies to produce specific proteins and peptides tailored for research or therapeutic purposes.

These services offer scalability from small research quantities to large-scale manufacturing, enabling drug developers to produce molecules with specific sequences and modifications.

This flexibility supports preclinical and clinical research, expediting the development of new therapies.

What are the key differences between protein and peptide synthesis?

Protein synthesis is generally more complex than peptide synthesis due to the larger size and intricate folding of proteins.

Proteins are usually produced using recombinant DNA technology in cells, whereas peptides are synthesized chemically.

Peptide synthesis allows for rapid and scalable production, while protein synthesis requires sophisticated techniques to ensure proper folding and activity.

How do recombinant DNA and hybridoma technologies facilitate protein production?

Recombinant DNA technology involves inserting genes that encode specific proteins into host cells, enabling large-scale production.

Hybridoma technology, on the other hand, allows for the creation of monoclonal antibodies by fusing specific white blood cells with hybridoma cells.

Both technologies are critical for producing biologics, especially for cancer therapies and vaccines.

What role do GMP standards play in protein and peptide synthesis?

Good Manufacturing Practice (GMP) standards ensure that the production of proteins and peptides meets strict regulatory requirements for safety, purity, and efficacy.

GMP compliance is essential in pharmaceutical manufacturing to ensure the consistent quality of therapeutic products, especially for clinical trials and commercial distribution.

For full details (including contact details) on the leading companies within this space, download the free Buyer’s Guide below: